SOPH
NASDAQSOPHiA GENETICS SA
Price$5.23-0.05 (-1.04%)
01:30 PM06:00 PM
News · 26 weeks108+33%
2025-11-022026-04-26
Mix9390d
- Insider75(81%)
- SEC Filings9(10%)
- Other6(6%)
- Earnings3(3%)
Latest news
25 items- INSIDERChief Medical Officer Menu Philippe sold $24,089 worth of Ordinary Shares (5,000 units at $4.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 261,388 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Van Well Daan4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Xu Zhenyu4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Valente Manuela4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Menu Philippe4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Camblong Jurgi4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Muken Ross4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Puylaert Kevin4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi
- SECSEC Form 144 filed by SOPHiA GENETICS SA144 - SOPHiA GENETICS SA (0001840706) (Subject)
- INSIDERSEC Form 4 filed by Camblong Jurgi4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Xu Zhenyu4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Menu Philippe4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Muken Ross4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRMount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026SAN DIEGO and NEW YORK, April 16, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai's Molecular Pathology team will leverage SOPHiA DDM™
- INSIDERSEC Form 4 filed by Xu Zhenyu4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Van Well Daan4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Camblong Jurgi4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Muken Ross4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Menu Philippe4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Van Well Daan4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Xu Zhenyu4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Valente Manuela4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Menu Philippe4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by Muken Ross4 - SOPHiA GENETICS SA (0001840706) (Issuer)
SOPH FAQ
7 questionsWhat does SOPHiA GENETICS SA do?
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.Where does SOPH stock trade?
SOPHiA GENETICS SA (SOPH) is listed on NASDAQ.What sector and industry is SOPH in?
SOPHiA GENETICS SA operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SOPHiA GENETICS SA go public?
SOPHiA GENETICS SA (SOPH) completed its IPO in 2021.What are analysts saying about SOPH?
SOPHiA GENETICS SA has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1100.00 price target on 2024-12-18.What companies are similar to SOPH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SOPH side-by-side with any of them on Quantisnow.How can I track SOPH on Quantisnow?
Quantisnow aggregates SOPHiA GENETICS SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOPH to receive live email and push alerts on every new disclosure.